Analysis: the details provided in regards to this particular complaint indicate that the physician (s) felt that the flixene graft occluded too early.There was no supporting information regarding this claim and there were no images of the actual occlusion(s) presented to justify this claim.Multiple questions were sent to the physicians but none of the questions were answered after 3 good faith requests for more detailed information.The questions asked were relevant to the reported event and the procedure in order to better understand the circumstances surrounding the complaint.One email correspondence from dr.(b)(6) and dr.(b)(6) with regards to their 8 complaints about early occlusion after implantation of flixene grafts in the last 4 months they mentioned the following: ¿that this occlusion may not be product related but related to the implant area in the arm and maybe related to kinking or something else.¿ the response also included that the physicians were not going to be able to provide any further information regarding the events.As indicated in the instructions for use (ifu) the adverse reactions that could occur are the following: ¿adverse reactions: complications that may occur in connection with the use of any vascular graft include, but are not limited to; thrombosis, stenosis, formation of pseudo aneurysm due to excessive needle punctures, peri-graft hematoma formation, peri-graft seroma formation, excessive needle hole bleeding or weeping, infection, swelling of tissue, suture hole elongation, mechanical disruption, material separation, delamination or tearing of the graft material, suture line or host vessel which may result in extreme blood loss, loss of limb function, steal syndrome, loss of limb or possible death.The patient should be advised to contact the physician should an adverse reaction occur.¿ a review of the device history records for this production lot of grafts shows that there were no non-conformances during the manufacture of the grafts and that all quality and performance requirements were met.Conclusion: based on the review of the device history records and product complaint details atrium medical corporation cannot conclude that the manufacture or design of the products were directly related to the occlusion of the graft.As thrombus formation and stenosis are adherent risks of this procedure as indicated in the adverse event section of the ifu.H3 other text : not available for return.
|